Mutual of America Capital Management LLC Sells 7,681 Shares of Johnson & Johnson (NYSE:JNJ)

Mutual of America Capital Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 317,395 shares of the company's stock after selling 7,681 shares during the quarter. Johnson & Johnson makes up approximately 0.5% of Mutual of America Capital Management LLC's investment portfolio, making the stock its 21st largest position. Mutual of America Capital Management LLC's holdings in Johnson & Johnson were worth $51,437,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Innealta Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $27,000. Highline Wealth Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. Morton Brown Family Wealth LLC lifted its position in shares of Johnson & Johnson by 400.0% during the 3rd quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company's stock valued at $41,000 after acquiring an additional 200 shares during the period. Finally, MFA Wealth Advisors LLC bought a new position in shares of Johnson & Johnson in the second quarter worth $43,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 1.4 %

NYSE:JNJ traded up $2.13 during trading hours on Friday, hitting $154.00. 11,328,515 shares of the company were exchanged, compared to its average volume of 6,621,219. The company has a fifty day simple moving average of $161.35 and a 200 day simple moving average of $156.10. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The stock has a market capitalization of $370.77 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 2.74 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.66 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. Johnson & Johnson's dividend payout ratio (DPR) is currently 71.78%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on JNJ shares. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Citigroup lifted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the company a "buy" rating in a research note on Wednesday, October 16th. Daiwa America downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 23rd. Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday. They issued an "outperform" rating and a $190.00 target price on the stock. Finally, Daiwa Capital Markets cut shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.